Fiasp (fast-acting insulin aspart) / Novo Nordisk - LARVOL DELTA

A Pilot Outpatient Assessment of a Fully Closed-Loop Insulin and Pramlintide System. (PubMed, J Diabetes Sci Technol) - "This study suggests that automated insulin and pramlintide systems have the potential to alleviate carbohydrate counting without degrading time in range. A longer and larger study is underway."

Clinical • Journal • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

Comparison of the effectiveness of fast-acting insulin aspart with rapid-acting insulin analogues on glycaemic control: a retrospective cohort study using patient data from primary care practices in England. (PubMed, BMJ Open) - "Reductions in HbA1c were numerically larger with faster aspart in three of four subgroups. There was higher treatment persistency with faster aspart vs rapid-acting insulin analogues among T1D switchers."

Clinical • Journal • Retrospective data • Diabetes • Endocrine Disorders • Hypoglycemia • Metabolic Disorders • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus

Sensor-Derived Glycemic Metrics in Women with Type 1 Diabetes Using Insulin Degludec Versus Other Basal Insulin Analogs During Pregnancy-A Post Hoc Analysis of the CopenFast Trial. (PubMed, Womens Health Rep (New Rochelle)) - "The use of faster-acting insulin aspart and insulin aspart was equally distributed in the two groups. Birthweight standard deviation score was 1.5 ± 1.2 versus 0.8 ± 1.1 (p = 0.01). In this post hoc analysis, pregnant women with type 1 diabetes using degludec achieved lower nighttime TIRp, experienced less severe hypoglycemia, and delivered infants who were heavier and thereby had less appropriate size compared with women using other basal insulin analogs."

Journal • Retrospective data • Diabetes • Hypoglycemia • Metabolic Disorders • Severe Hypoglycemia • Type 1 Diabetes Mellitus

Aging with type 1 diabetes: a perspective on "octagenarians" living with type 1 diabetes in Italy (EASD 2025) - "Among patients treated with the conventional basal-bolus insulin regimen, most (76.5%) were treated with second-generation basal insulin (glargine U300 or degludec). The most used rapid insulin analogues were lispro (44%), aspart (32.4%), glulisine (10%), and faster aspart (11.9%)... Many people with type 1 diabetes have aged, becoming 'octogenarians' by being regularly followed up in Italian diabetes centers. The overall quality of care for patients regularly followed up has resulted in a lower-than-expected burden of end-stage renal disease, visual loss, and diabetic foot. Management of CV risk factors could be improved."

Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

Cross-cultural reliability and validation of the Factors Affecting Compliance with Standard Precautions Scale-student version (ChiCTR) - P=N/A | N=480 | Completed | Sponsor: The Fifth Affiliated Hospital of Southern Medical University; The Fifth Affiliated Hospital of Southern Medical University

Compliance • New trial

A Pilot Study Evaluating Meal Timing, Macronutrient Composition, and Faster-Acting Insulin Aspart Versus Insulin Aspart on Postprandial Glycemia with the Medtronic Advanced Hybrid Closed-Loop System. (PubMed, Diabetes Technol Ther) - P | " For adults with type 1 diabetes who are susceptible to morning hyperglycemia, FiAsp delivered by AHCL and higher fat content of meals may help improve postprandial glycemic outcomes. Clinical Trial Registration: Australian New Zealand Clinical Trials Registry-ACTRN12619001340123."

Journal • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

Cross-cultural adaptation and psychometric evaluation of the factors influencing adherence to the standard precautions scale - Student version (FIASP-SV) for Saudi Arabian nursing students. (PubMed, Int J Nurs Stud Adv) - "The FIASP-SV is a reliable and valid tool for assessing factors influencing nursing students' adherence to SPs in Saudi Arabia. This tool has significant implications for developing targeted educational interventions to improve SP practices among nursing students in Arabic-speaking contexts."

Journal • Infectious Disease

Intraperitoneal Insulin Partially Restores Growth Hormone Response to Hypoglycemia (ADA 2025) - "Participants fasted overnight before receiving ~40% of their total daily dose (TDD) Fiasp® through ultrasound-guided IP injection at 2 visits, and SQ injection at 1 visit... IP insulin partially restores growth hormone secretion and reduces peripheral insulin levels during hypoglycemia, potentially providing a therapeutic avenue for PwT1D prone to severe hypoglycemia."

Hypoglycemia • Metabolic Disorders • Severe Hypoglycemia • Type 1 Diabetes Mellitus

MiniMed 780G System Use with Fast-Acting Insulin Aspart by Adults with T1D (ADA 2025) - "These findings show that Fiasp is safe when used with MM780G AHCL and provides improved glycemic outcomes when compared to RAI with open-loop or HCL use."

Clinical • Metabolic Disorders • Severe Hypoglycemia

Efficacy of Ultra-rapid and Rapid-Acting Insulin Analogs in Hybrid and Advanced Automated Insulin Delivery Systems among People with Type 1 Diabetes—A Systematic Review and Meta-analysis of Randomized Controlled Trials (ADA 2025) - "Inclusion criteria were RCTs; T1D populations of any age; comparing URIAs (Fiasp® or Lyumjev®) with any type of RIAs; using any type of AID systems. URIAs safely improved glycemia and were comparable to RIAs among T1D people using AID systems. Despite outcomes demonstrating statistical significance, the clinical impact may be small, given the TIR improvement of 1.4% (registration ID: CRD42024578754)."

Metastases • Retrospective data • Review • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

Comparison of Pharmacodynamics and Pharmacokinetics of Insulin Aspart and Faster-Acting Insulin Aspart around Continuous Moderate Intensity Exercise in Adults with Type 1 Diabetes—A Randomised Controlled Trial (ADA 2025) - "Participants maintained usual morning insulin degludec. Reduced insulin aspart or faster-acting aspart showed similar PD/PK characteristics around continuous moderate intensity cycling in adults with T1D."

Clinical • PK/PD data • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

Fully Closed-Loop Improves Glycemic Control Compared with Pump with CGM in Adolescents with Type 1 Diabetes and HbA1c Above Target: A Two-Center, Randomized Crossover Study. (PubMed, Diabetes Technol Ther) - "We evaluated the use of FCL with faster insulin aspart (Fiasp) in adolescents with T1D whose HbA1c was above recommended targets...No severe hypoglycemia or ketoacidosis occurred. FCL insulin delivery with CamAPS HX improved glucose outcomes compared with insulin pump therapy with CGM in adolescents with T1D and HbA1c above target."

Journal • Diabetes • Metabolic Disorders • Severe Hypoglycemia • Type 1 Diabetes Mellitus

Comparing Medicare Maximum Fair Prices with Other Drug Prices in Other Countries (ISPOR 2025) - " The comparison showed that the costs of the 10 drugs included in the Part D negotiations (Januvia, Fiasp/NovoLog/NovoRapid insulin products, Farxiga/Forxiga, Enbrel, Jardiance, Xarelto, Eliquis, Entresto, Stelara, and Imbruvica) were still lower in other countries even after price negotiations. Despite substantial discounts provided by Medicare price negotiations, US maximum fair prices remain generally higher than prices applied in other countries with high healthcare spending per capita. A limitation of the analysis is the approximation of monthly drug costs without utilization data."

Medicare • Reimbursement • US reimbursement

Targeted, Rapid Glycaemic Control and Its Potential Adverse Outcomes (ESPE-ESE 2025) - "Treatment with daily subcutaneous injections of insulin degludec and ultra-fast-acting insulin aspart was continued at the woman’s request. Conclusion . This case highlights the importance of pregnancy planning for women with T1D and hypoglycaemia unawareness, particularly after delivery when insulin sensitivity undergoes dramatic changes."

Adverse events • Cardiovascular • Diabetes • Hypoglycemia • Metabolic Disorders • Respiratory Diseases • Type 1 Diabetes Mellitus

Afrezza® INHALE-1 Study in Pediatrics (clinicaltrials.gov) - P3 | N=319 | Completed | Sponsor: Mannkind Corporation | Active, not recruiting ➔ Completed

Trial completion • Diabetes • Metabolic Disorders • Pediatrics • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus

Faster-acting insulin aspart versus insulin aspart for adults with type 1 diabetes treated with non-automated insulin pump and continuous glucose monitoring-A double-blind randomized controlled crossover trial. (PubMed, Diabetes Obes Metab) - "Faster aspart improved baseline-adjusted TIR, TAR, CV and HbA1c after 16 weeks with frequent insulin pump adjustments but had a higher incidence of injection site reactions."

Journal • Diabetes • Metabolic Disorders • Severe Hypoglycemia • Type 1 Diabetes Mellitus

RANDOMISED OPEN-LABEL CLINICAL TRIAL EXAMINING THE SAFETY AND EFFICACY OF THE ANDROID ARTIFICIAL PANCREAS SYSTEM WITH ADVANCED BOLUS-FREE FEATURES: THE CLOSE IT TRIAL (ATTD 2025) - "Full results will be available for presentation at ATTD 2025."

Clinical • Metastases • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

SENSOR-DERIVED GLYCEMIC METRICS IN WOMEN WITH TYPE 1 DIABETES USING INSULIN DEGLUDEC VS. OTHER BASAL INSULIN ANALOGS DURING PREGNANCY (ATTD 2025) - "The use of faster-acting insulin aspart and insulin aspart was equally distributed in the two groups. Severe hypoglycemia occurred in 1 (2%) vs. 5 (17%) (p=0.01). Birthweight standard deviation score was 1.5 ±1.2 vs. 0.8± 1.1 (p=0.01).Conclusions In this post-hoc analysis pregnant women with type 1 diabetes using insulin degludec achieved lower night-time TIRp, experienced less severe hypoglycemia and delivered infants who had less appropriate size compared to women using other basal insulin analogs."

Clinical • Diabetes • Metabolic Disorders • Severe Hypoglycemia • Type 1 Diabetes Mellitus

FAST-ACTING INSULIN ASPART INCREASES MAINLY THE TIME IN TIGHT RANGE AMONG T1DM INDIVIDUALS USING AN AUTOMATIC INSULIN PUMP (ATTD 2025) - "TITR's value increased from 41.6% to 47.5% (p<0.01).Conclusions Both TIR and TITR improved by 6-6%. The improvement in CGM data was mainly due to an increase in TITR, i.e., an increase in the time spent in normoglycemia."

Clinical • Type 1 Diabetes Mellitus

FAST-ACTING INSULIN ASPART IN ADULTS USING AN ADVANCED HYBRID CLOSED LOOP SYSTEM (ATTD 2025) - "While FA is associated with similar overall glycemic control to IAsp in AHCL, its use corresponds to more TIR70-180 after a meal challenge."

Clinical • Metastases • Hypoglycemia

USE OF ADVANCED HYBRID CLOSED LOOP SYSTEM (AHCLS) IN A PATIENT WITH MEN1 SYNDROME AND PANCREATOGENIC DIABETES: A CASE REPORT (ATTD 2025) - "He was educated in counting carbohydrates for meal coverage and an AHCLS Minimed 780G was placed with faster aspart insulin...Gradual amelioration is still being observed resulting also in better quality of life: TIR:90%, TAR:10%, TBR:0%, GMI:6,5% CV:22.9%, HbA1c: 6,8%Conclusions This case demonstrates that AHCLS can be beneficial in patients with PD enabling optimal glucose levels without high degree of hypoglycemia. Further studies should be conducted in order to determine the effectiveness of AHCLS in this rare group of patients."

Case report • Clinical • Metastases • Diabetes • Endocrine Cancer • Hypoglycemia • Metabolic Disorders • Oncology • Solid Tumor

INFLUENCE OF DIETS DIFFERING IN MACRONUTRIENT COMPOSITION ON ENERGY METABOLISM DURING SUSTAINED, SUBMAXIMAL EXERCISE IN ADULTS WITH TYPE 1 DIABETES (ATTD 2025) - "This study profiled the metabolic responses to fasted submaximal cycling in adults with T1D following 7-days of adherence to diets differing in macronutrient composition.Methods In a randomised crossover design, 12 adults with T1D (n=4 female, age: 46±15 years, HbA1c: 55.9±7.8 mmol/mol) managed by non-automated insulin pump (n=9 Novorapid, n=3 Fiasp) consumed three diets over 7-days: HCLFLP (high carbohydrate (48%), low fat (33%), low protein (19%)), LCHFLP (low carbohydrate (19%), high fat (62%), low protein (19%)) and LCLFHP (low carbohydrate (19%), low fat (57%), high protein (24%)). Carbohydrate oxidation was greater in HCLFLP compared to LCHFLP (p=0.030), with concomitantly lower lipid oxidation (Table 1, p=0.030). Conclusions A 7-day low carbohydrate diet influenced fasted exercise metabolism with lower carbohydrate oxidation and circulating fatty acids despite similar glycaemic patterns in adults with T1D."

Clinical • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

CLOSE IT - Results from a randomized controlled fully closed loop trial (ATTD 2025) - "Twenty FCL arm participants will participate in a 4-week extension phase comparing NovoRapid® (insulin aspart) to Fiasp® (insulin aspart and niacinamide). Baseline data include median age 36 years (interquartile range, IQR 26-46), 48% female gender, median diabetes duration 19 years (IQR 11-30), 46% existing insulin pump users, median HbA1c 57mmol/mol (IQR 50-63). Conclusions Full results will be available for presentation at ATTD 2025."

Clinical • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

FULLY CLOSED-LOOP IMPROVES GLYCAEMIC CONTROL COMPARED TO PUMP WITH CGM IN ADOLESCENTS WITH TYPE 1 DIABETES AND HBA1C ABOVE TARGET: A TWO-CENTRE, RANDOMISED CROSSOVER STUDY (ATTD 2025) - "Participants underwent two 8-week periods of unrestricted living comparing FCL (CamAPS HX) with faster-acting insulin aspart (Fiasp) with standard insulin pump therapy with CGM in random order...No severe hypoglycaemia or DKA events occurred. Conclusions Fully closed-loop insulin delivery with CamAPS HX improved glucose control compared with insulin pump therapy with CGM in adolescents with T1D and HbA1c above target."

Clinical • Diabetes • Metabolic Disorders • Severe Hypoglycemia • Type 1 Diabetes Mellitus

Fully closed-loop - Insulin only approaches (ATTD 2025) - "Investigations performed with ultra-rapid insulin analogs (faster-aspart and ultra-rapid lispro) have shown so far variable and limited improvements of glucose control and patient satisfaction, depending of the AID system, participant age and tested ultra-rapid analog...A revision of control algorithms adapted to this new ecosystem is also needed. These exploratory pathways seem likely to allow ultimately fully closed-loop using insulin-only approaches."

Diabetes • Metabolic Disorders